{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:14:39Z","timestamp":1763968479992,"version":"3.44.0"},"reference-count":50,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify the therapeutic range for etanercept and to assess the incidence of anti-etanercept antibody formation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Associations between etanercept serum concentration and disease activity as well as treatment response were examined in a longitudinal observational study of rheumatoid arthritis patients starting etanercept. Disease activity was assessed by ultrasound (grey scale and power Doppler), 28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index, plasma calprotectin and C reactive protein. Etanercept concentration and anti-etanercept antibodies were analysed using automated in-house fluorescence assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 89 patients were included, whereof 66% were biological disease-modifying antirheumatic drug (DMARD) na\u00efve and 91% used concomitant synthetic DMARD. At 3 months, the median etanercept concentration was 1.8 (IQR 1.1\u20132.5)\u2009mg\/L. Longitudinal associations were found between etanercept concentration and disease activity assessed by plasma calprotectin, C reactive protein and DAS28, but not between etanercept concentration and improvement in disease activity by any of the parameters at 3, 6 or 12 months of treatment. Etanercept concentrations were not significantly different among patients who achieved response or remission, compared with non-response or non-remission. Hence, no therapeutic range could be identified. None of the patients developed anti-etanercept antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite the use of sensitive and objective markers of inflammation, a therapeutic range could not be identified for etanercept. Hence, this study suggests that proactive therapeutic drug monitoring is unlikely to benefit rheumatoid arthritis patients treated with etanercept, but a potential benefit in certain clinical situations cannot be excluded.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001985","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:50:33Z","timestamp":1639569033000},"page":"e001985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-0223","authenticated-orcid":false,"given":"Johanna Elin","family":"Gehin","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silje Watterdal","family":"Syversen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David John","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guro L\u00f8vik","family":"Goll","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-8991","authenticated-orcid":false,"given":"Hilde Berner","family":"Hammer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"2025090313092387000_7.3.e001985.1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090313092387000_7.3.e001985.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20019"},{"key":"2025090313092387000_7.3.e001985.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"2025090313092387000_7.3.e001985.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"2025090313092387000_7.3.e001985.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2025090313092387000_7.3.e001985.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2009-5","article-title":"Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"21","author":"Gehin","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090313092387000_7.3.e001985.7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","article-title":"Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"50","author":"Gehin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025090313092387000_7.3.e001985.8","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2025090313092387000_7.3.e001985.9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/BOR.0000000000000487","article-title":"Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts","volume":"30","author":"den Broeder","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025090313092387000_7.3.e001985.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200184"},{"key":"2025090313092387000_7.3.e001985.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175207","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"key":"2025090313092387000_7.3.e001985.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203893"},{"key":"2025090313092387000_7.3.e001985.13","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-207530","article-title":"Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study","volume":"74","author":"Sanmarti","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090313092387000_7.3.e001985.14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313092387000_7.3.e001985.15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","article-title":"Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study","volume":"57","author":"Balsa","year":"2018","journal-title":"Rheumatology"},{"key":"2025090313092387000_7.3.e001985.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"2025090313092387000_7.3.e001985.17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","article-title":"52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis","volume":"56","author":"Emery","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313092387000_7.3.e001985.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023929"},{"key":"2025090313092387000_7.3.e001985.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex036"},{"key":"2025090313092387000_7.3.e001985.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152926"},{"key":"2025090313092387000_7.3.e001985.21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/03009742.2020.1845394","article-title":"Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis","volume":"50","author":"Hammer","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025090313092387000_7.3.e001985.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064741"},{"key":"2025090313092387000_7.3.e001985.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103739"},{"key":"2025090313092387000_7.3.e001985.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1201-0","article-title":"Calprotectin (S100A8\/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis","volume":"19","author":"Nordal","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090313092387000_7.3.e001985.25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23339","article-title":"Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients","volume":"70","author":"Hammer","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090313092387000_7.3.e001985.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090313092387000_7.3.e001985.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090313092387000_7.3.e001985.28","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313092387000_7.3.e001985.29","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"2025090313092387000_7.3.e001985.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh297"},{"key":"2025090313092387000_7.3.e001985.31","article-title":"Scores for all seasons: SDAI and CDAI","volume":"32","author":"Smolen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313092387000_7.3.e001985.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew385"},{"key":"2025090313092387000_7.3.e001985.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2025090313092387000_7.3.e001985.34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0000000000000580","article-title":"A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients","volume":"41","author":"Klaasen","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2025090313092387000_7.3.e001985.35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/sji.12572","article-title":"Assays for Infliximab Drug Levels and Antibodies: A matter of scales and categories","volume":"86","author":"Bader","year":"2017","journal-title":"Scand J Immunol"},{"key":"2025090313092387000_7.3.e001985.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.11.008"},{"key":"2025090313092387000_7.3.e001985.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1032-z","article-title":"Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity","volume":"18","author":"Inciarte-Mundo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313092387000_7.3.e001985.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4205"},{"key":"2025090313092387000_7.3.e001985.39","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010375961"},{"key":"2025090313092387000_7.3.e001985.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.002"},{"key":"2025090313092387000_7.3.e001985.41","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.4049\/jimmunol.178.Supp.131.22","article-title":"Determination of affinity constants of adalimumab infliximab and etanercept for soluble and membrane forms of TNF using kinetic exclusion assay (131.22)","volume":"178","author":"Sakorafas","year":"2007","journal-title":"J Immunol"},{"key":"2025090313092387000_7.3.e001985.42","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313092387000_7.3.e001985.43","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313092387000_7.3.e001985.44","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19126"},{"key":"2025090313092387000_7.3.e001985.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"2025090313092387000_7.3.e001985.46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","article-title":"Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement","volume":"13","author":"Bouman","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025090313092387000_7.3.e001985.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208849"},{"key":"2025090313092387000_7.3.e001985.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206588"},{"key":"2025090313092387000_7.3.e001985.49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","article-title":"The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors","volume":"38","author":"Mart\u00ednez-Feito","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313092387000_7.3.e001985.50","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268049"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:09:45Z","timestamp":1756930185000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,12,15]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/rmdopen-2021-001985"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001985","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}